Facebook
Twitter
LinkedIn
ForwardAnil Pillai, M.D
- Personal Statement
I am an academic interventional radiologist specializing in image-guided interventional treatments. I first became interested in managing patients with Hepatocellular carcinoma(HCC) when I was a fellow in interventional radiology at Rush University Medical Center, where a portion of my time was spent in presenting cases in a multi-disciplinary tumor board. This opened my eyes to the limitations of the available treatment options for these patients. After my fellowship I continued as a faculty at Rush University Medical center for the next 5 years. I was the lead interventional radiologist in my group for interventional oncology. Managing patient with hepatocellular carcinoma has been a humbling experience. The currently available treatments are limited and the chance of a cure for this cohort of patients is very small. Although many novel treatments have been introduced in the recent past including drug eluting beads and radioembolization, the outcomes have not changed significantly.
My experience has encouraged me to look for other options for the treatment of Hepatocellular cancer. I have worked with other PIs and submitted R21 and CPRIT grants for looking at liver directed treatments for HCC. I have also done retrospective studies looking at outcomes after treatment of HCC with drug eluting beads and Y 90. The gap in knowledge from my clinical and research experience is in identifying the tumor biology to directed treatment. With this goal in mind I have approached the problem from the angle of identifying tumor biomarkers which will predict the tumor response. I believe that this will give us the opportunity to choose the right treatment for the right patient.
The outcome of patients with Hepatocellular carcinoma is very poor and it is of critical importance to develop new techniques to improve quality of life, reduce morbidity of treatment and prolong survival. In this project I will be collaborating with Dr. Hongyu Wang one of my colleagues who has extensive experience with Aptomer design and tumor biomarker identification. Our combined clinical and lab experience, coupled with the expertize of the advanced imaging center at UT Houston Health Science center provides the ideal environment to develop novel tools to enhance the treatment of these patients.
- Positions and Honors
Position and Employment
07/1998 – 06/2002 Staff Radiologist, Amrita Institute of Medical Sciences, Kochi, India
10/2002 – 07/2003 Consultant Radiologist, Al Ahalia Hospital, Abudhabi, United Arab Emirates
11/2003 – 06/2005 Consultant Radiologist, Burnley General Hospital, Lancashire, United Kingdom.
07/2005 – 06/2007 Fellow, Rush University Medical Center, Chicago, IL
07/2007 – 12/2012 Attending, Rush University Medical Center, Chicago, IL
07/2011 – 12/2012 Associate Director, Section of Interventional Radiology, Rush University Medical Center, Chicago, IL
01/2013 – 09/2016 Assistant Professor, UT Southwestern Medical Center, Dallas, TX
04/2013 –03/2016 Medical Director, Interventional Radiology, Parkland Memorial Hospital, Dallas, TX
09/2016- Present Associate Professor, UT Houston Health Science Center, Houston TX
09/2016- Present Section Chief, UT Houston Health Science Center, Houston TX
Other Experience and Professional Memberships
2004 – Present Radiological Society of North America (RSNA), Member
2006 – 2009 American Roentgen Ray Society (ARRS), Member
2005 – Present Society of Interventional Radiology (SIR, formerly SCVIR)) Member
2005 – Present American College of Radiology, Member
2003 – Present Fellow of Royal College of Radiologist UK
1998 – Present Indian Radiological and Imaging Association
Honors
1998 Diplomate of National Board of Radiology National Board of Examinations, New Delhi, India
2003 Fellow of Royal College of Radiology (FRCR) Royal College of Radiologist, London, UK
2011 Certificate of Added Qualification (CAQ) American Board of Radiology
2014 Magna Cum Laude Radiological Society of North America
2014 Certificate of Merit Radiological Society of North America
2014 Best Educational Exhibit Society of Interventional Radiology
2014 Certificate of Merit Society of Interventional Radiology
2014 Best Educational Exhibit Global Embolization Symposium &Technologies
2014 Physicians Vascular interpretation (RPVI) American Registry for Diagnostic Medical Sonography (ARDMS)
2015 Harvey L Neiman Grant Society of Interventional Radiology
2015 Certificate of Merit Society of Interventional Radiology
2015 Certificate of Merit Radiological Society of North America
2016 Certificate of Merit Society of Interventional Radiology
2016 Certificate of Merit Society of Interventional Radiology
2016 Mentor: Constantine Cope Research Award Society of Interventional Radiology
2016 Mentor: Resident in training research Award Society of Interventional Radiology
2017 Best Educational Exhibit Society of Interventional Radiology
2017 Best Educational Exhibit Association of University Radiologist
2018 Runner up for the best Scientific Research Paper Journal of Vascular and Interventional Radiology
- Contribution to Science:
- We compared overall survival and toxicities after yttrium-90 (90Y) radioembolization and chemoembolization with drug-eluting embolics (DEE) in patients with infiltrative hepatocellular carcinoma (HCC) in a retrospective study.We did find that DEE was associated with more grade 1&2 toxicities but the overall survival was not different in the 2 groups. This study proves that new technology has not impacted the overall survival of patients with infiltrative HCC. However, the toxicity profile has improved. The key is in patient selection based of tumor biology. Thus the search for identifying the patients who will benefit from different treatments based on tumor biology.
Selected Peer-reviewed Publications
- Single-Center Comparison of Overall Survival and Toxicities in Patients with Infiltrative Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization or Drug-Eluting Embolic Transarterial Chemoembolization. Joseph L. McDevitt,Ali Alian, , Baljendra Kapoor, Stacy Bennett, Amanjit Gill, Abraham Levitin, Mark Sands, K.V. Narayanan Menon, Federico N. Aucejo, Bassam Estfan, Anil K. Pillai, Sanjeeva P. Kalva, Gordon McLennan JVIR 2017 July PMID 28689934
- Yttrium-90 Radioembolization of Hepatic Metastases from colorectal cancer Raval M, Bande D, Pillai AK, Ganguli S, Blaszkowsky LS, Beg MS, Kalva SP Front Oncol.2014 25:4:120 PMID 25120951
- I have contributed to several Quality Improvement initiatives in clinical practice to set benchmarks. Some of the efforts are in the field of oncology to determine the ideal time for exchange of nephrostomy tubes. In our research we have shown a difference in outcomes in cancer and non-cancer patients. This research also showed that the optimal time to do a tube exchange in patients with cancer is between 40 and 60 days. Previously there has not been a data driven protocol for this process. This paper was awarded the runner up best research paper in the Journal of Vascular and Interventional Radiology in 2017.
Selected Peer-reviewed Publications
- Long-Term Percutaneous Nephrostomy Management of Malignant Urinary Obstruction: Estimation of Optimal Exchange Frequency and Estimation of the Financial Impact of Patient Compliance. McDevitt JL, Acosta-Torres S, Zhang N, Hu T, Odu A, Wang J, Xi Y, Lamus D, Miller DS, Pillai AK. JVIR J Vasc Interv Radiol. 2017 Apr doi: 10.1016/j.jvir.2017.02.031. PMID: 28385361
- Comparative evaluation of non-procedural nephrostomy -related complications in patients with ureteric obstruction due to cancer versus other causes: Is the protocol of routine 3-month nephrostomy exchange optimal for both disease processes? T Hu, N Zhang, J McDevitt,A Odu, Y Xi, D Lamus, AK Pillai JCIR 2017
- I have contributed to the development of a six sigma tool to evaluate process in interventional radiology. For instance, my paper of utilizing DMAIC methodology to increase IVC filter retrieval has been in place for over 3 years. The national retrieval rates are very low. One of the reasons for the poor retrieval rates is poor patient follow up. We utilized a quality improvement tool namely Define, Measure, Analyze, Implement and Control to improve the filter retrieval rates for IVC filters in our institution. The filter retrieval rates prior to implementing this program was 8% and this increased to 52% after an automated system of scheduling patients for a clinic follow up was implemented. This was also associated with increase revenue to the section. This project was presented at the 2014 SIR meeting and was awarded first prize. This article underscores the utilization of quality improvement tools to improve processes in interventional radiology. It describes by example how a Quality improvement project can be done utilizing the DMAIC methodology.
Selected Peer-reviewed Publications
- Improving inferior vena cava filter retrieval rates with the DMAIC methodology. P Sutphin, S Reis, A Mckune, M Ravanzo, SP Kalva, Pillai AK JVIR 2015;26: 491-98 PMID25636673
- Approaching the Practice Quality Improvement Project in Interventional Radiology Reis SP, White B, Sutphin PD, Pillai AK, Kalva SP, Toomay SM. J Am Coll Radiol.2015,(PMID26337461)
- Safety and Effectiveness of Denali Inferior Venacaval Filter: Intermediate Follow up results Reis SP, Kovoor J, Sutphin PD,Toomay S, Trimmer C, Pillai AK, Reddick M, Kalva SP Vasc Endovascular Surg 2016,Aug 31 PMID 27581228
- I have introduced innovative methods to do difficult procedures to reduce complications and improve outcomes. For instance, I have popularized the use of Intravascular ultrasound to gaining access to the portal vein. The research published in the Journal of Vascular and Interventional radiology in transforming the technique of performing the Transjugular intrahepatic portosystemic shunt creation. I have had several invited talks to demonstrate these new innovative techniques.
Selected Peer-reviewed Publications
- Utility of Intravascular US-Guided Portal vein access during transjugular intrahepatic portosystemic shunt creation: Retrospective Comparison with conventional technique in 109 patients. Pillai AK, Andring B, Faulconer N, Reis SP, Xi Y,Iyamu I, Sutphin PD, Kalva SP J Vasc Interv Radiol 2016, 27: 1154-9 PMID 27363298
- Portal Hypertension: A review of portosystemic collateral pathways and endovascular interventions: Pillai AK, B Andring, A Patel, C Trimmer, S Kalva Clin Radiol 2015 July (PMID 26188844)
- A retrospective analysis of technical factors influencing patency of Transjugular intrahepatic portosystemic shunts: Does the distance between the venous end of the stent and the hepatocaval junction matter in the era of Stent-grafts. World Journal of Gastroenterology 2015 Jul 14;21(26): 811—7 .B Andring, Kalva SP, Sutphin P, A Anene, R Sinivas, Burell M, Xi Y, Pillai AK(PMID 26185383)
- I have also introduced the technique of directly accessing the thoracic duct from the neck for lymphangiograms. The intranodal lymphangiograms are performed to take care of lymphatic leaks. This procedure is new and directly accessing the thoracic duct was not previously described.
Selected Peer-reviewed Publications
- Interventional radiology in the management of thoracic duct injuries: Anatomy, techniques and results. Toliyat M, Singh K, Sibley RC, Chamarthy M, Kalva SP, Pillai AK Clin Imaging. 2017 Jan 3;42:183-192.PMID 28103513
- Direct Percutaneous Access to the Cervical Portion of the Thoracic Duct, an Alternate to Traditional Access through the Cisterna Chyli. Reis SP, Macfurlane J,Anene A,Pillai AK J Vasc Interv Radiol 2015;12:1902-4 (PMID 26596185)
A complete list of my peer reviewed publication can be viewed at
https://www.ncbi.nlm.nih.gov/labs/bibliography/1doyk3zEFI9kf/bibliography/public/
D. Research Support
Completed Research Support
Grantor: Society of Interventional Radiology
Title of Project: “Improving Quality of Care for Patients with Percutaneous Nephrostomy through a Dedicated Interventional Radiology Driven Follow-up Program”.
Role of the Nominee: Principal Investigator
Annual amount and date (direct costs only): $30,000
Total Award Amount: $30,000; 6/1/2015-5/31/2016 I year
Grantor: Nordian/BTG
Title of Project: A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver Who Have Failed First Line Chemotherapy
Role of the Nominee: Institutional Principal Investigator
Annual amount and date (direct costs only): None, company sponsored Clinical trial;
Grantor: Gore Medical
Title of Project: Endoprosthesis versus Percutaneous Transluminal Angioplasty (PTA) to Revise Arteriovenous Grafts at the Venous Anastomosis in Hemodialysis Patients (Gore REVISE study).
Role of the Nominee: Institutional Principal Investigator
Annual amount and date (direct costs only): None, company sponsored Clinical trial; 2009-2012
Grantor: Gore Medical
Title of Project: The GORE VIATORR TIPS endoprosthesis versus Large-Volume Paracentesis for the treatment of ascites in patients with portal hypertension.
Role of the Nominee: Institutional Principal Investigator
Annual amount and date (direct costs only): None, company sponsored Clinical trial; 2011-2013
Ongoing Research Support:
Grantor: Society of Interventional Oncology
Title of Project: “Identify Proteomic Biomarkers for Outcome Prediction of Lipoidol TACE ”.
Role of the Nominee: Principal Investigator
Annual amount and date (direct costs only): $100,000
07/01/2018-06/31/2020 2 years
Financial relationships
**Disclaimer**
This Continuing Medical Education (CME) Learning Management System, Ethos, includes individuals designated as 'faculty' for CME purposes. Please note that the term 'faculty' refers solely to their role as a contributor/planner within a CME activity and does not imply any formal affiliation with UT Southwestern Medical Center (UTSW). The display of names and credentials is intended for educational purposes only and does not necessarily indicate a professional or academic relationship with UTSW. Participants are encouraged to verify the affiliations and credentials of faculty members independently if further clarification is needed.